PolyTherics Receives Second Patent Allowance in Record Time

07-Jul-2009 - United Kingdom

PolyTherics Limited announced that a second patent has been allowed covering the targeted PEGylation of proteins. Issued by the United States Patent Office, this allowance protects PolyTherics’ PEGylation technology in the two largest pharmaceutical markets in the world. This news comes two weeks after the allowance of the first patent within Europe.

The patent claims the use of a unique linker developed at PolyTherics that enables precision attachment of PEG to natural disulfide bonds in proteins. Trademarked as TheraPEG™, the technology allows proteins with proven therapeutic efficacy such as Interferons, erythropoietin and antibody fragments to remain active and potent in the body for longer, resulting in less frequent dosing without loss of biological activity. TheraPEG™ has been shown to be a highly efficient, reliable and cost effective process which complements the proven cost benefits of bacterial expression to produce therapeutic proteins.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances